Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 7/20 | 0.47 |
| ▸ | NSD2 | O96028 | 3/20 | 0.47 |
| ▸ | MITF | O75030 | 2/20 | 0.47 |
| ▸ | APAF1 | O14727 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | CDC25A | P30304 | 3/20 | 0.44 |
| ▸ | TOP1 | P11387 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31029510 | 0.84 | MAPT (0.66) | MALT1MAPTNSD2MITFAPAF1 | |
| SCHEMBL10894074 | 0.84 | MAPT (0.66) | MALT1MAPTNSD2MITFAPAF1 | |
| SCHEMBL20046780 | 0.77 | CDC25A (0.70) | MAPTNSD2MITFAPAF1NPC1 | |
| SCHEMBL29587040 | 0.77 | MALT1 (0.62) | MALT1MAPTNSD2NPC1RAB9A | |
| SCHEMBL7557626 | 0.77 | MALT1 (0.62) | MALT1MAPTNSD2NPC1RAB9A | |
| SCHEMBL6052671 | 0.77 | MALT1 (1.00) | MALT1MAPTNSD2MITFAPAF1 | |
| SCHEMBL31218590 | 0.77 | MALT1 (0.62) | MALT1MAPTNSD2NPC1RAB9A | |
| SCHEMBL9209216 | 0.74 | TOP1 (0.59) | MALT1MAPTBRCA1SMN1; SMN2HIF1A | |
| Hydrochloric Acid SCHEMBL9208228 | 0.73 | TOP1 (0.58) | MALT1MAPTBRCA1SMN1; SMN2HIF1A | |
| SCHEMBL3418752 | 0.73 | MAPT (0.63) | MALT1MAPTNSD2RAB9ABRCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11459313-B2 | Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2022-10-04 | — | — | US | disclosed |
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-10 | — | — | US | disclosed |
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE | 2020-09-10 | — | — | US | disclosed |
| WO-2018067842-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200283417-A1 | AZIRIDINYL AND AMINO DIMERIC NAPHTHOQUINONE COMPOUNDS AND USE FOR ACUTE MYELOID LEUKEMIA | MCL1, NPM1, ABL1 | MALT1 1468/4885MAPT 4723/4885NSD2 327/4885 |
| US-11459313-B2 | Aziridinyl and amino dimeric naphthoquinone compounds and use for acute myeloid leukemia | MCL1, NPM1, ABL1 | MALT1 1468/4885MAPT 4723/4885NSD2 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.